| Assessment Status | Rapid Review Complete |
| HTA ID | 23007 |
| Drug | Foslevodopa/foscarbidopa |
| Brand | Produodopa® |
| Indication | Foslevodopa/foscarbidopa (Produodopa®) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. |
| Assessment Process | |
| Rapid review commissioned | 13/02/2023 |
| Rapid review completed | 27/03/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Produodopa® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations March 2024.
